• Policy
• SK Bioscience gets final approval for SKYCovione
• by Lee, Hye-Kyung Jun 30, 2022 05:52am

• Opinion
• [Reporter's view] Negotiation of Zolgensma
• by Jun 30, 2022 05:52am

• Company
• Opdivo reattempts reimb in first-line gastric cancer
• by Eo, Yun-Ho Jun 29, 2022 05:54am

• Policy
• ↑The cost of drugs for severe dz by ₩1.79 trillion
• by Lee, Tak-Sun Jun 29, 2022 05:53am

• Policy
• Fexclu reimb at ₩939, Kadcyla reimb extended from July
• by Kim, Jung-Ju Jun 29, 2022 05:53am

• Company
• Celltrion Stops Developing Inhalation-type COVID Antibody Tx
• by Kim, Jin-Gu Jun 29, 2022 05:53am

• Company
• Patent challenge for gastritis drug Rebamipide expanded
• by Kim, Jin-Gu Jun 29, 2022 05:53am

• Policy
• Low strength Esomezole Plus Tab priced same as Eso Duo
• by Lee, Tak-Sun Jun 28, 2022 06:09am

• Policy
• Phase 3 of Danicopan will be conducted in Korea
• by Lee, Hye-Kyung Jun 28, 2022 06:09am

• Policy
• The first COVID-19 vaccine is expected to be approved
• by Lee, Hye-Kyung Jun 28, 2022 06:09am